The most typical cytogenetic aberration in myelodysplastic syndromes is del(5q), which, when isolated, is associated with refractory anaemia and good prognosis. Based on high rates of erythroid response and transfusion independence, Lenalidomide (LEN) became the standard treatment. This multi-centre study was designed to supplement Italian Registry data on LEN by addressing prescription, administration appropriateness, haematological and cytogenetic responses and disease evolution.

Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency / Arcioni F.; Roncadori A.; Di Battista V.; Tura S.; Covezzoli A.; Cundari S.; Mecucci C.; Abbadessa A.; Alterini R.; Santini V.; Cantonetti M.; Buccisano F.; Bacigalupo A.; Sessarego M.; Tonso A.; Ferrero D.; D'Ardia S.; Tarella C.; Cascavilla N.; Bassan R.; Sancetta R.; Cortelezzi A.; Reda G.; Maria D'Arco A.; De Fabritiis P.; Di Renzo N.; Falini B.; Alimena G.; Avanzini P.; Ilariucci F.; Iuliano F.; La Nasa G.; Caocci G.; Defina M.; Latte G.; Palmas A.; Levis A.; Leone G.; Teresa Voso M.; Leoni P.; Poloni A.; Fozza C.; Crugnola M.; Montanaro M.; Spedini P.; Lanza F.; Pizzuti M.; Pane F.; Paolini R.; Borin L.; Rambaldi A.; Rossi G.; Maria Pelizzari A.; Russo D.; D'Emilio A.; Ruggeri M.; Semenzato G.; Specchia G.; Tagariello G.; Sartori R.; Testore F.; Ciravegna G.; Marasca R.; Cimarosto L.; Fontanive O.; Visani G.. - In: EUROPEAN JOURNAL OF HAEMATOLOGY. - ISSN 0902-4441. - STAMPA. - 101:(2018), pp. 78-85. [10.1111/ejh.13067]

Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency

Alterini R.;Santini V.;CIRAVEGNA, GABRIELE;
2018

Abstract

The most typical cytogenetic aberration in myelodysplastic syndromes is del(5q), which, when isolated, is associated with refractory anaemia and good prognosis. Based on high rates of erythroid response and transfusion independence, Lenalidomide (LEN) became the standard treatment. This multi-centre study was designed to supplement Italian Registry data on LEN by addressing prescription, administration appropriateness, haematological and cytogenetic responses and disease evolution.
2018
101
78
85
Arcioni F.; Roncadori A.; Di Battista V.; Tura S.; Covezzoli A.; Cundari S.; Mecucci C.; Abbadessa A.; Alterini R.; Santini V.; Cantonetti M.; Buccisa...espandi
File in questo prodotto:
File Dimensione Formato  
ejh.13067_LENA 5q.pdf

accesso aperto

Descrizione: Articolo
Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 527.23 kB
Formato Adobe PDF
527.23 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1176254
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 2
social impact